GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (STU:2QA) » Definitions » Change In Receivables

Altamira Therapeutics (STU:2QA) Change In Receivables : €0.02 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Altamira Therapeutics Change In Receivables?

Altamira Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was €0.08 Mil. It means Altamira Therapeutics's Accounts Receivable declined by €0.08 Mil from Jun. 2023 to Dec. 2023 .

Altamira Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €0.02 Mil. It means Altamira Therapeutics's Accounts Receivable declined by €0.02 Mil from Dec. 2022 to Dec. 2023 .

Altamira Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Altamira Therapeutics's liquidation value for the six months ended in Dec. 2023 was €-0.66 Mil.


Altamira Therapeutics Change In Receivables Historical Data

The historical data trend for Altamira Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Change In Receivables Chart

Altamira Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.24 -0.33 -0.11 0.02

Altamira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 0.02 -0.13 -0.07 0.08

Altamira Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics  (STU:2QA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Altamira Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/-0.111*91
=

2. In Ben Graham's calculation of liquidation value, Altamira Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Altamira Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.654-1.311+0.75 * 0+0.5 * 0
=-0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics (STU:2QA) Business Description

Traded in Other Exchanges
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics (STU:2QA) Headlines

No Headlines